Ponatinib is a novel potent, orally available small molecule multitargeted kinase inhibitor. Ponatinib inhibits both native and mutant BCR-ABL. Ponatinib is used in the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors. Ponatinib
Molecular Weight:
532.56
Purity:
99% (HPLC)
Form:
White to off-white powder
CAS Number:
[943319-70-8]
* VAT and and shipping costs not included. Errors and price changes excepted